Trial Profile

A three arm, prospective study to compare the effect of six weeks exposure to the combination of lopinavir (LPVr)/Combivir (AZT [zidovudine]/3TC [lamivudine]) versus lopinavir alone or Combivir alone in HIV-negative healthy subjects on the development of abnormalities of lipid and glucose metabolism

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lamivudine/zidovudine (Primary) ; Lopinavir/ritonavir (Primary) ; Lopinavir
Indications HIV infections
Focus Adverse reactions; Biomarker; Pharmacodynamics
Acronyms SAMA002

06 Mar 2013 Pooled analysis of bone turnover markers presented at the 20th Conference on Retroviruses and Opportunistic Infections.
11 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12605000661673).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com